Last reviewed · How we verify

Bupivicaine alone

The Cleveland Clinic · Phase 3 active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses. Used for Local anesthesia for infiltration, nerve block, and regional anesthesia procedures.

At a glance

Generic nameBupivicaine alone
SponsorThe Cleveland Clinic
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhasePhase 3

Mechanism of action

Bupivacaine reversibly binds to and blocks voltage-gated sodium channels on the inner surface of nerve cell membranes, preventing depolarization and action potential generation. This results in local anesthesia and loss of sensation in the area where it is administered. The drug has a relatively long duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: